X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA PIRAMAL ENTERPRISES ELDER PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x -0.2 8.5 - View Chart
P/BV x 0.1 1.5 6.6% View Chart
Dividend Yield % 0.0 1.1 -  

Financials

 ELDER PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
PIRAMAL ENTERPRISES
Mar-18
ELDER PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs3803,083 12.3%   
Low Rs1881,902 9.9%   
Sales per share (Unadj.) Rs491.2589.7 83.3%  
Earnings per share (Unadj.) Rs-3.2284.0 -1.1%  
Cash flow per share (Unadj.) Rs14.4310.5 4.6%  
Dividends per share (Unadj.) Rs025.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs376.51,467.0 25.7%  
Shares outstanding (eoy) m20.54180.27 11.4%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x0.64.2 13.7%   
Avg P/E ratio x-89.38.8 -1,017.2%  
P/CF ratio (eoy) x19.78.0 245.5%  
Price / Book Value ratio x0.81.7 44.4%  
Dividend payout %08.8 0.0%   
Avg Mkt Cap Rs m5,833449,332 1.3%   
No. of employees `000NA6.8 0.0%   
Total wages/salary Rs m2,17919,881 11.0%   
Avg. sales/employee Rs ThNM15,535.6-  
Avg. wages/employee Rs ThNM2,905.4-  
Avg. net profit/employee Rs ThNM7,482.5-  
INCOME DATA
Net Sales Rs m10,089106,310 9.5%  
Other income Rs m2572,595 9.9%   
Total revenues Rs m10,346108,906 9.5%   
Gross profit Rs m-79251,599 -1.5%  
Depreciation Rs m3614,773 7.6%   
Interest Rs m2,75629,783 9.3%   
Profit before tax Rs m-3,65319,638 -18.6%   
Minority Interest Rs m02,801 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m125-28,764 -0.4%   
Profit after tax Rs m-6551,203 -0.1%  
Gross profit margin %-7.848.5 -16.2%  
Effective tax rate %-3.4-146.5 2.3%   
Net profit margin %-0.648.2 -1.3%  
BALANCE SHEET DATA
Current assets Rs m9,240118,154 7.8%   
Current liabilities Rs m9,998462,260 2.2%   
Net working cap to sales %-7.5-323.7 2.3%  
Current ratio x0.90.3 361.6%  
Inventory Days Days4627 174.2%  
Debtors Days Days6047 128.8%  
Net fixed assets Rs m10,124113,727 8.9%   
Share capital Rs m206361 57.1%   
"Free" reserves Rs m5,582264,093 2.1%   
Net worth Rs m7,734264,454 2.9%   
Long term debt Rs m4,889242,206 2.0%   
Total assets Rs m22,882726,834 3.1%  
Interest coverage x-0.31.7 -19.6%   
Debt to equity ratio x0.60.9 69.0%  
Sales to assets ratio x0.40.1 301.5%   
Return on assets %11.811.1 105.5%  
Return on equity %-0.819.4 -4.4%  
Return on capital %22.310.3 216.5%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m30715,110 2.0%   
Fx outflow Rs m1254,298 2.9%   
Net fx Rs m18110,813 1.7%   
CASH FLOW
From Operations Rs m11,754-159,666 -7.4%  
From Investments Rs m-561-17,677 3.2%  
From Financial Activity Rs m-6,762186,503 -3.6%  
Net Cashflow Rs m4,4329,364 47.3%  

Share Holding

Indian Promoters % 39.6 52.9 74.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 4.0 187.5%  
FIIs % 16.8 26.6 63.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 16.5 218.8%  
Shareholders   16,479 93,274 17.7%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   FRESENIUS KABI ONCO.  AJANTA PHARMA  ALEMBIC LTD  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare ELDER PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY19); Net Profit Up 59.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 59.3% YoY). Sales on the other hand came in at Rs 31 bn (up 24.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY19); Net Profit Down 152.5% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 1 bn (down 152.5% YoY). Sales on the other hand came in at Rs 29 bn (up 28.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS